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Introduction I have made considerable progress on the research project that I outlined in the predoctoral DOD breast cancer research fellowship proposal. The proposal aimed to determine targets for the ubiquitin ligase activity of BRCAI. BRCA1 (Breast Cancer susceptibility gene 1) is an important tumor suppressor that protects mammary cells from malignant transformation. Recently BRCA1 has been found to have an enzymatic function as an ubiquitin ligase. Ubiquitin ligases tag other proteins with a small peptide, ubiquitin, and these tagged proteins then signal for downstream events such as protein degradation or DNA repair. Determination of the targets for ubiquitination by BRCA1 will lead to a better understanding of how this protein performs its tumor suppressor function.
Body and key research outcomes The specific aims for this project are as follows:
Identify targets for ubiquitination by BRCA1
A. Biochemical experiments: use of purified BRCAl -containing complexes and ubiquitin activating and conjugating enzymes for in vitro reactions to determine which proteins are ubiquitinated by BRCAI.
B. Biological experiments: use of HCC1937 cells, which contain a truncated form of BRCA1 to test the function of the carboxy-terminus in the regulation of ubiquitination. 2. Reconstitution of BRCA1 ubiquitination in a pathway in vitro.
Progress for aim 1A. We have developed a powerful in vitro ubiquitination system using purified ubiquitin activating enzyme (El), ubiquitin conjugating enzyme UbcH5c (E2), purified ubiquitin and BRCA1 co-purified with its heterodimeric binding partner BARD1 (BRCA1 Associated RING Domain protein 1). We have applied this in vitro system to an observation that we have made in which inhibition of BRCA1 in breast cells results in an amplification of centrosome number. We have determined that ytubulin associated with purified centrosomes is a target for BRCAl/BARD1 ubiquitination (see Figure 1) . In order to assay the importance of the ubiquitination of y-tubulin on centrosome integrity, we used mass spectrometry to determine which lysines of the y-tubulin molecule were ubiquitinated by BRCAl/BARDI. We then mutated the lysine 48 and/or 344 to arginine and expressed these mutant y-tubulin genes in cells. The results show that when y-tubulin K48R is expressed in cells centrosomes become amplified after 48 hours (see Figure 2) . These results suggest that ubiquitination of y-tubulin at lysine 48 by BRCAI/BARD1 is necessary for maintenance of centrosome number and integrity. Proper centrosome duplication and spindle formation are crucial to prevent chromosomal instability, a hallmark of cancer cells, and BRCA1 has a role in this process.
Using this in vitro ubiquitination system we have also determined that phosphorylated RNA pol II is also targeted by BRCA1 for ubiquitination. BRCA1 is known to co-purify with RNA pol 11. Interestingly, BRCA1 also plays a role in DNA damage repair suggesting that BRCA1 may be a genome surveillance protein scanning the genome as a passenger on RNA pol 11. 
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Progress for aim lB. We are using HS578T breast cell lines that are transfected with siRNA targeted against BRCA1 to confirm whether the targets for ubiquitination found in vitro are important in vivo. Assays for immunoprecipitating ubiquitinated proteins are still being optimized. We are also developing a means to identify all of the proteins in the centrosome that are ubiquitinated by BRCA1.
Progress for aim 2. Reconstitution of BRCA1 ubiquitination function in a pathway in vitro.
We have made some progress on this aim. We had proposed in the original application that BRCA1 was a component in a DNA damage sensing mechanism whereby DNA damage would be detected by transcription by RNA polymerase II as it synthesized mRNA. BRCA1 and BARD1, present in the complex would then ubiquitinate the polymerase and signal for the initiation of damage repair. We have data, which support this model. First, there is the in vitro ubiquitination assay described above (Figure 3 ). These data are consistent with the pathway that we propose. The second line of evidence is that we have found that in cells, inhibition of transcription elongation signals to the cell that there is DNA damage. We are currently determining whether this pathway depends on functional BRCA1.
Reportable Outcomes: Publications resulting from DAMD17-02-1-0306 We anticipate submitting a manuscript describing the ubiquitination of RNA polymerase II by BRCA1/BARD1 in the near future. In addition, I am second author on two research papers, one that is in the revision stage after primary submission and one that will be submitted within several weeks. 
Conclusions
We have developed a highly active and highly specific BRCAl-dependent ubiquitination assay for in vitro assays. Using this novel experimental system, we have identified two substrates: centrosomes and RNA polymerase I1. We have begun to characterize the biochemical pathway in which BRCA1-dependent ubiquitination activity regulates centrosome function and thereby protects the cells from cancerous transformation. This is outstanding progress in the second year of this fellowship towards achieving the goals of this project.
Appendix
See enclosed a Molecular and Cellular Biology manuscript supported in part from this fellowship.
Proper centrosome duplication and spindle formation are crucial for prevention of chromosomal instability, and BRCA1 plays a role in this process. In this study, transient inhibition of BRCA1 function in cell lines derived from mammary tissue caused rapid amplification and fragmentation of centrosomes. Cell lines tested that were derived from nonmammary tissues did not amplify the centrosome number in this transient assay. We tested whether BRCA1 and its binding partner, BARD1, ubiquitinate centrosome proteins. Results showed that centrosome components, including y-tubulin, are ubiquitinated by BRCAl/BARD1 in vitro. The in vitro ubiquitination of -y-tubulin was specific, and function of the carboxy terminus was necessary for this reaction; truncated BRCA1 did not ubiquitinate -/-tubulin. BRCAl/BARD1 ubiquitinated lysines 48 and 344 of -/-tubulin in vitro, and expression in cells of y,-tubulin K48R caused a marked amplification of centrosomes. This result supports the notion that the modification of these lysines in living cells is critical in the maintenance of centrosome number. One of the key problems in understanding the biology of BRCA1 has been the identification of a specific target of BRCAl/BARD1 ubiquitination and its effect on mammary cell biology. The results of this study identify a ubiquitination target and suggest a biological impact important in the etiology of breast cancer.
Cancer cells frequently have unstable numbers of chromocentrosome in mitotic cells (17, 23) . Second, interference with somes (reviewed in reference 20). One mechanism for chro-BRCA1 function by various methods can cause an increased mosomal instability is improper centrosome duplication, since centrosome number. For example, mouse fibroblasts derived the centrosome is the organelle that organizes the spindle for from BRCA1 exon 11 knockouts have amplified centrosomes separation of chromosomes during mitosis. The presence of (46). Amino acid residues 504 to 803 of BRCA1 bind y-tubumore than two centrosomes in a cell can result in lost or lin, a major component of centrosomes, and stable overexpresfragmented chromosomes after cell division. Human tumors sion of the -y-tubulin binding domain of BRCA1 causes cenderived from breast and other tissues have abnormal centrotrosome amplification in tissue culture cells (16) . BRCA1 some numbers in early-stage lesions. As an example, abnormal function can be inhibited by a peptide that binds to its carboxy centrosome numbers have been detected in ductal carcinoma terminus. Acute expression of this peptide causes a rapid rise in situ, the first stage of breast cancer (21, 33) , and BRCA1 has in centrosome number in a mammary cell line (36). been shown to have a role in regulating centrosome number BRCA1 is an 1,863-amino-acid protein with BRCT repeats (reviewed in reference 9).
at its carboxy terminus; at its amino terminus is a RING do-BRCA1 is a tumor suppressor that is mutated in inherited main, which is a powerful ubiquitin ligase when this domain of breast and ovarian cancer cases, and it is also epigenetically BRCA1 is associated with BARD1 (15, 45) . Candidate subdown-regulated in sporadic breast cancers. Strikingly, BRCA1
strates identified in vitro include autoubiquitination of function is required for nearly all cell types to grow; it has BRCA1/BARD1 and monoubiquitination of histone monomany roles in the cell. These functions include the regulation mers and of the p53 protein (8, 10, 25) . The cellular conseof DNA damage repair, transcription, and X-chromosome inquences of the BRCA1/BARDl-mediated ubiquitination of activation (reviewed in references 37 and 41). All of these these substrates remain unclear. processes could be important in protecting mammary cells
In this study, we inhibited BRCA1 function in several tissue from uncontrolled growth, but it is not clear why loss of culture cell lines and found that the mammary tissue-derived BRCA1 specifically results in breast and ovarian cancer.
cell lines rapidly accumulated extra centrosomes after BRCA1 There is growing evidence that BRCA1 functions as a reginhibition. Intriguingly, BRCA1 inhibition did not result in ulator of centrosome number. First, BRCA1 is localized to the centrosome amplification in the nonmammary cell lines that we tested. Since BRCA1 and BARD1 together constitute a ubiquitin ligase, we tested whether BRCA1I/BARD1 ubiquiti-* Corresponding author. B3RCA1 is an important step in the regulation of centrosomes.
ton Biochem), histidine-tagged with a lysine 48 mutation to arginine (Boston Biochem), or purified bovine ubiquitin (Sigma). The centrosome fraction (400 ng) with the largest amount of y-tubulin was added to the reaction mixtures as indicated. In reaction mixtures containing purified recombinant y-tubulin or MATERIALS AND METHODS centrin, the individual proteins were added at 700 ng each. Reaction mixtures Cell culture. MCF1OA, T47D, ZR75-1, HS578T, U20S, HeLa, PC3, and were incubated at 37°C for 30 min, and then proteins were resolved on protein DLD-1 tissue culture cells were cultured according to American Type Culture gels and blotted to polyvinylidene difluoride membranes. Total ubiquitinated Collection recommendations. MTSV1-7 cells were a gift from J. Taylor-Papadproteins were visualized by using streptavidin fused to horseradish peroxidase imitriou (Cancer Research UK, Guy's Hospital, London, United Kingdom) and (HRP) and chemiluminescence. Ubiquitinated 'y-tubulin was visualized by Westwere cultured according to established protocols (4) . Cells were infected with em blotting with mouse anti--y-tubulin (Sigma) followed by chemiluminescence. adenovirus as described previously (36) at a multiplicity of infection of 200 to 400
Antibodies specific for ct-and e-tubulin were purchased from Sigma. Streptavidin PFU/cell. The virus expressing BRCA1 interfering peptide fragment (BIF) was affinity purification was performed according to standard protocols (Dynal). compared to viruses expressing either green fluorescent protein (GFP) or LacZ
The BRCA1 full-length and carboxy-terminal truncation proteins were balthat were infected at an equal multiplicity of infection. In comparisons of difanced by BARDI content. The BARD1 concentration in each reaction mixture ferent cell lines to MCF10A, the level of expression of the BIF peptide was equal.
was 15 nM, making the deduced BRCA1 concentration 15 nM in each ubiquitiSmall interfering RNA (siRNA) transfection was performed by using Oligonation reaction. In the experiment for which results are shown in Fig. 6B , BIF or fectamine (Invitrogen), and cells were harvested 2 days posttransfection. The control peptide was added at two concentrations for each protein fragment, 900 control oligonucleotide targets luciferase mRNA (5' to 3', AAC GUA CGC nM and 3.5 jiM. GGA AUA CUU CGA), the BRCAI-a oligonucleotides have been published Mass spectroscopy. Excised gel bands were subjected to trypsin proteolysis; elsewhere (14) , and the BRCAI-b oligonucleotide target is BRCA1 mRNA (5' MS/MS spectra of resulting peptides were acquired by nanoscale microcapillary to 3', AAG GUU UCA AAG CGC CAG UCA) (Dharmacon). Lipofectamine LC-MS/MS as described previously (31) on an LTQ-DECA mass spectrometer 2000 (Invitrogen) was utilized for transfection of "y-tubulin and GFP-centrin (ThermoElectron). Spectra were searched with the SEQUEST (11) algorithm plasmids.
against human entries from the Nonredundant Protein sequence database Immunofluorescence. Cells were fixed and stained with anti-y-tubulin (Sigma) (NRP), available from the National Center for Biotechnology Information. as described elsewhere (36). Centrin staining is described in reference 22. Images were viewed at an original magnification of X400 or X1,000 with a Zeiss Axioscope and were captured by using a model 2.3.1 SPOT digital camera. The indicated cell lines either were infected with a control adenovirus expressing either GFP or LacZ (a, c, e, g, i, k, m, and o) or were infected with an adenovirus expressing BIF at an equal multiplicity of infection (b, d, f, h, j, 1, n, and p). Twenty-four to 27 h after infection, cells were fixed and stained for DNA content (DAPI; blue) and with an antibody specific to yý-tubulin (a to n) (red). Centrosomes were also stained with an antibody specific to centrin (o and p) (red). (B) The cells from the experiments for which results are shown in panel A were counted, and the percentage of cells with amplified (more than two) centrosomes were scored. Results of one representative experiment are shown. The number of cells with more than two centrosomes was determined at least twice for each cell line, and at least 100 cells were counted in each experiment. The data were collected from ýy-tubulin-stained cells for the first nine experimental pairs and from centrin-stained cells for the last pair on the right (Hs578T, centrin). large subunit of RNA polymerase II (Pol II) in order to evaluate equal status of these cell lines correlates with the centrosome ampliloading of samples. (B) Cells with more than two centrosomes were fication phenotype is important, since p53 plays a role in censcored by fluorescence microscopy as for Fig. lB . The histogram shows trosome number regulation, and p53 is known to interact with the percentage of cells with amplified centrosomes. (C) Cells were BRCA1 pathways (13, 47) . It should be noted that several cell fixed and stained with an antibody specific to ýy-tubulin (as for Fig. 1A ) 48 h after transfection with BRCA1-directed siRNA (BRCAI-b oligolines with mutant p53 could not be used in this study because nucleotide). Examples of mitotic Hs578T cells (a and b) and U2OS they had centrosome amplification independent of BIF exprescells (c) are shown. sion.
In analysis of the centrosome number in cells by use of an antibody specific to y-tubulin, it is possible that fragmentation, of centrosome replication and the proper maintenance of the rather than replication, of centrosomes was scored as extra centrosome structure require BRCA1 function in this cell line. centrosomes. In order to test this possibility, the experiment There is supporting evidence that the effects of BIF expresfor which results are shown in Fig. lAa and b was repeated, but sion on centrosome number reflected an inhibition of BRCA1. the cells were stained with an antibody specific to centrin.
BIF interferes with BRCA1 localization after DNA damage, Centrin is located at each centriole, and by immunofluoresand cells that lack wild-type BRCA1 (HCC1937) show a simcence each centrosome should have two pinpoints of centrin. ilar centrosome amplification phenotype (36). Nevertheless, it Normal cells with one or two centrosomes would have two or is possible that BIF alone, and not its interaction with BRCA1, four points of centrin in pairs. It was found that Hs578T cells caused centrosome amplification. To use a third method to test expressing the control protein had no examples of cells with whether BRCA1 is indeed necessary for proper centrosome more than four centrin-positive spots in two pairs. By contrast, maintenance in mammary cells, siRNA oligonucleotides were expression of BIF in these cells resulted in a rapid increase in designed to decrease the expression of BRCA1. The Western the number of cells with more than four centrin-positive spots blot in Fig. 2A shows that the two different siRNA oligonucle-(9%), and these were frequently found not to be in pairs (Fig. otide pairs directed against BRCA1, but not a control siRNA, lAo-p). These results suggest that both the proper regulation significantly reduced the amount of BRCA1 protein in trans- Fig. 1 and 2 ). BRCA1 has also been shown to localize to centrosomes during mitosis and to bind to n-tu-6 .. bulin by coimmunoprecipitation (16) . BRCA1, together with -----BARD1, forms a heterodimer associating via the respective 12hl RING domains and adjacent ot-helices of each protein, and the a L9 .1 ............................. ...................................................................................... ........ ............ ..... ... ......... .... ....... ubiquitin. Reaction products were resolved on protein gels and infection with adBIF or adLacZ. Cells were fixed and stained for transferred to polyvinylidene difluoride membranes, and ubi--y-tubulin at 12, 18, and 24 h postinfection (hpi). The histogram shows quitinated species were identified by using streptavidin conjuthe percentage of cells with abnormal centrosome numbers. gated to HRP. In Fig. 4A , lane 2, autoubiquitination of BRCA1 (>220 kDa) is apparent along with ubiquitination of a 110-kDa polypeptide, which may be BARD1. In the presence fected Hs578T and U2OS cells. To determine if a reduction in of centrosomes, El, UbcH5c, and ubiquitin but no BRCAl/ BRCA1 levels by siRNA caused amplified centrosomes, the BARDI, no ubiquitinated species were apparent (lane 3). Adnumber of cells with abnormal centrosome numbers was dition of BRCA1/BARD1 to these reaction mixtures resulted scored by immunofluorescence using a -y-tubulin-specific antiin four or more new ubiquitinated products (lane 4). Comparbody. The results summarized in Fig. 2B show that Hs578T ison with the total polypeptide composition of the centrosome mammary cells that have reduced BRCA1 levels have a 5-to preparation (data not shown) reveals that only a subset of the 10-fold increase in the fraction of cells with more than two centrosome-associated proteins was modified by ubiquitin. centrosomes. Figure 2C shows examples of mitotic Hs578T
One of the ubiquitinated polypeptides had a migration concells with amplified centrosomes. While the expression of sistent with monoubiquitinated -y-tubulin (48 kDa unmodified BRCA1 was reduced to the same level in U2OS cells, centroplus 8 kDa of ubiquitin). To determine whether the ubiquitisomes from this cell line were not amplified. This suggests that nated species at 56 kDa (Fig. 4A, lane 4) was -y-tubulin, the the centrosome amplification phenotype caused by siRNA same ubiquitination reaction, including the centrosome fracknockdown of BRCA1 followed the same mammary cell-spetion, BRCA1/BARD1, El, UbcH5c, and biotinylated ubiqcific trend observed for expression of BIF. This also suggests uitin, was analyzed for modification of -y-tubulin. Monoclonal that the function of BRCA1 at the centrosome is inhibited by antibodies to -y-tubulin were used to detect unmodified y-tu-BIF binding.
bulin at 48 kDa in lanes containing centrosomes (Fig. 4B , lanes HU abolishes centrosome amplification in cells expressing 3 and 4), and in the presence of BRCA1/BARD1, a shifted BIF. As an initial characterization of the centrosome amplifipolypeptide consistent with monoubiquitinated -y-tubulin was cation in these mammary epithelial cell lines expressing BIF, apparent (lane 4). To test whether the reaction was specific for we asked whether passage through the cell cycle is important -y-tubulin, we also analyzed reaction products for ubiquitinafor the increase in centrosome number. It is known that cention of the related a-and s-tubulin polypeptides, and they were trosome duplication in mammalian cells is dependent on the negative for BRCAl/BARDl-dependent ubiquitination under activity of cyclin A (27) . Thus, passage through S phase of the these conditions (Fig. 4C) . These results suggest that -y-tubulin cell cycle would be critical to duplicate the centrosomes if the is a specific target of BRCAl/BARD1 for ubiquitination. BIF-dependent amplification was utilizing the normal cellular In order to define the specificity of the BRCA1/BARD1 machinery for this duplication process. This was tested directly ubiquitination reactions for -y-tubulin, we tested as substrates by treating cells with hydroxyurea (HU), which blocks cells -y-tubulin and centrin-1, which had been expressed and purified early in S phase, and assaying centrosome amplification, from bacteria. Equal amounts of recombinant protein were MCF10A cells were infected at time zero with adBIF or a included in reaction mixtures containing BRCA1/BARD1, El, control, and HU was added after 3 h. The centrosome number UbcH5c, and ubiquitin. Dependent on the presence of was scored by immunofluorescence for -y-tubulin at 12, 18, and BRCA1/BARD1, the y/-tubulin band was shifted by 8 and 16 24 h postinfection (hpi). In the absence of HU, amplification of kDa, consistent with ubiquitination (Fig. 4D) . By contrast, centrosomes in these cells was apparent after 18 h. HU blocked inclusion of BRCA1/BARD1 along with the other ubiquitinathe amplification of centrosomes when added to the medium tion factors showed no modification of the centrin protein ( Fig.  after adBIF infection (Fig. 3) . These results suggest that treat-4D). This result implies that BRCA1/BARD1 specifically modment of cells with HU halted the cell cycle upstream of the ifies -y-tubulin, either as a purified protein or in association point at which BRCA1 affected centrosome replication, with the centrosome. Interestingly, purified -y-tubulin was modThe BRCA1/BARD1 heterodimer ubiquitinates centrosome ified by one or two ubiquitin moieties, whereas centrosomeproteins in vitro. Our data clearly indicate that BRCA1 exeassociated -y-tubulin was only modified by one ubiquitin mol- Ub--+ubufln 4t1t. ecule. It is possible that the recombinant protein has a second site that is monoubiquitinated, whereas the -y-tubulin in the was anticipated because y-tubulin is present as a multimer in centrosome would have the second site blocked, large multisubunit complexes in centrosomes (-y-tubulin ring In order to test whether the slower-migrating band in reaccomplex [-y-TuRC]). An inference from the presence of the tions using centrosome fractions was in fact a ubiquitin modunmodified -y-tubulin associated with the monoubiquitinated ification, the requirement for ubiquitination factors was tested.
-y-tubulin is that the modification does not disrupt the -y-TuRC In the complete reaction, a band at 56 kDa was detected by complex.
using an antibody specific for -y-tubulin (Fig. 5A, lane 1) . Omis-BRCA1/BARD1 monoubiquitinates 'y-tubulin from centrosion of any single ubiquitination protein from the reaction somes in vitro. Polymerization of ubiquitin into chains requires resulted in a loss of the 56-kDa -y-tubulin species (Fig. 5A, isopeptide linkages between the activated carboxy terminus of lanes 2 to 5). Thus, the modification of -y-tubulin by BRCA1/ an incoming ubiquitin molecule and a lysine side chain of the BARD1 was also dependent on the presence of El, UbcH5c, protein substrate or the previously conjugated ubiquitin. and ubiquitin.
Isopeptide linkages via lysine 48 of four or more ubiquitin To ensure that the 56-kDa band detected by Western blotmolecules constitute a signal for proteasome-mediated degrating with anti--y-tubulin was indeed -y-tubulin plus biotinylated dation of the substrate protein. In order to facilitate easy ubiquitin, we utilized magnetic streptavidin beads to purify detection of ubiquitinated proteins, the ubiquitin used in Fig.  ubiquitinated proteins. Lanes 1 and 2 of Fig. 5B show the 4A to C and Fig. 5A and B was biotinylated via the amine products of the standard ubiquitination reaction before affinity group in the lysine side chains of ubiquitin. The ubiquitin, purification by streptavidin beads. Following purification using biotinylated via lysines, may inefficiently polymerize into mulstreptavidin beads, the 48-kDa -y-tubulin did not bind to the tiubiquitin chains. In order to address this issue, we compared matrix (lane 3). The 56-kDa band, dependent on BRCAl/ reactions that contained various ubiquitin molecules, including BARD1 in the reaction, was purified via the biotin-ubiquitin purified bovine ubiquitin, histidine-tagged-ubiquitin, and hismodification (lane 4). Unmodified y-tubulin (48 kDa) was also tidine-tagged-ubiquitin containing a mutation at lysine 48. In purified on the streptavidin beads in this reaction, although at reactions in which any of the purified ubiquitin proteins was a reduced level (lane 4). The presence of the 48-kDa -y-tubulin included, a 56-kDa band was observed, but ubiquitin polymers VOL. 24, 2004 BRCA1 UBIQUITINATION AND CENTROSOME NUMBER 8463
were not detected on -y-tubulin regardless of the type of ubiq-A. uitin used (Fig. 5C ). This suggested that the detection of mo-RING aRCA1 lIF Bindn~ domain noubiquitinated -y-tubulin was not due solely to a modification / ,M of ubiquitin. Increasing the amount of E2 factor or ubiquitin L 1R50 1800 also resulted in monoubiquitination (data not shown), suggest-1279 ing that the lack of a multiubiquitin chain was not due to limiting components in the reaction. It is possible that other OT4 factors not present in the reaction would cause the multiubiquitination of y-tubulin. Since the proteasome recognizes ubiq-C. eontrol poptile: BIF; uitin chains of four units or longer, linked through lysine 48, SRcA11ARM: -+ + . . . these data suggest that "y-tubulin ubiquitination by BRCA1/ 71"* BARD1 is not a signal for proteasome-mediated degradation. Fig. 6A ) were included in the complete lengths, shown in panel C, were added to ubiquitination reaction BRCA1/BARD1 ubiquitination reaction described above, mixtures as indicated and analyzed by Western blotting with anti--yWhile the control peptide had no effect on BRCA1/BARD1 tubulin. ubiquitination of -y-tubulin, the BIF peptide powerfully inhibited the BRCA1/BARDl-dependent ubiquitination of -y-tubulin (Fig. 6B ). This result shows that an unbound carboxy-BRCA1/BARD1 (Fig. 6D, lanes 4 to 6) . The requirement for terminal domain of BRCA1 is required for the ubiquitination full-length BRCA1 protein was striking, since the domains reaction.
55-
required for nonspecific ubiquitination and for y-tubulin bindTo test whether the carboxy terminus of BRCA1 is indeed ing reside in the amino-terminal 803 amino acids of BRCA1. necessary for ubiquitination of y-tubulin in vitro, we purified Expression in cells of y-tubulin with a mutant lysine 48 mutants of BRCA1 truncated at the carboxy terminus as hetresulted in centrosome amplification. The -y-tubulin residues erodimers associated with full-length BARDI. Protein prepamodified by BRCA1-dependent ubiquitination were deterrations included full-length BRCA1 (amino acids 1 to 1863), a mined by using the bacterially expressed y-tubulin (as in Fig.  cancer-associated truncation of BRCA1, BRCA1(1-1852) , and 4D) and mass spectroscopy of the ubiquitinated products. Lythree other truncations, BRCA1(1-1527), BRCA1(1-1000), sines 48 and 344 of y-tubulin were found to be modified ( Fig.  and BRCA1(1-500) , each coexpressed and purified with full-7A). We mutated these lysines to arginine, singly and together, length BARD1 protein. The BARD1 protein was untagged and expressed these "y-tubulin mutants by transient transfecand was purified via association with the tagged BRCA1. These tion in Hs578T mammary cells and in U20S osteosarcoma five BRCA1/BARD1 preparations were balanced for BARD1 cells. Western blotting of the epitope-tagged -y-tubulin mutants content (Fig. 6C) , and each was enzymatically active in a nonrevealed that they were all expressed well (Fig. 7B) . The y-tuspecific ubiquitin polymerization assay (data not shown). Each bulin K344R mutant was found to have a slowed migration, of these heterodimers was included in a ubiquitination reaction even though the DNA sequence revealed only the lysine-towith El, UbcH5c, biotinylated ubiquitin, and the centrosome arginine mutation. We tested whether transient transfection of fraction. Only the full-length BRCA1/BARD1 complex rothese -y-tubulin mutants affected the centrosome number by bustly ubiquitinated ,-tubulin (Fig. 6D, lane 2) . Ubiquitination cotransfecting GFP-centrin in order to analyze only cells that of -y-tubulin by the cancer-associated mutant that truncated the had been transfected. Remarkably, expression of these muprotein by only 11 amino acids, BRCA1(1-1852)/BARD1, was tated -y-tubulin proteins caused centrosome amplification ( Fig.  severely compromised (Fig. 6D, lane 3) . Trimming 336 or more 7C and D). The y,-tubulin K48R mutant had the most proamino acid residues from the carboxy terminus of BRCA1 ncunced effect on centrosome number after 48 h, causing a completely abolished the ubiquitination of y-tubulin by 2.5-fold increase in the number of cells with more than two centrosomes. On the other hand, expression of the -y-tubulin Hs578T cells, we conclude that -y-tubulin is a valid in vivo K344R mutant caused only a modest increase in the number of target of the BRCA1 ubiquitin ligase. The modification of cells with amplified centrosomes after 48 and 72 h. Expression -y-tubulin must be transient, since we did not detect ubiquitiof a mutant -y-tubulin containing both modified lysines caused nated -y-tubulin in cells (data not shown). These results with no effect after 48 h but a greater-than-twofold increase in the mutant -y-tubulin also support our hypothesis that the ubiqcentrosome number at the 72-h time point. We interpret the uitination of -y-tubulin and other centrosome targets is necesslowed centrosome amplification by the -y-tubulin double musary in order to protect mammary cells from aneuploidy. tant as a deficiency in localizing to the centrosome.
Is the apparent mammary specificity in centrosome amplifiExpression of the mutant y-tubulin in both Hs578T and cation the key to the breast-specific phenotype of BRCA1-U20S cell lines resulted in centrosome amplification. In fact, associated cancers? Such a conclusion cannot be drawn from the results from experiments with the two cell lines were nearly the results of this study. However, we do note that the reguidentical. This shows that the ubiquitination of -y-tubulin is lation of centrosome duplication depends in part on modificaimportant in both cell types but that the enzyme that mediates tion of lysine 48 of -y-tubulin and that, at least among some the ubiquitination may differ from cell type to cell type. Taking breast cell lines, this modification requires BRCA1. Published these findings together with the data from Fig. 1 and 2 , we findings report counterexamples to the apparent breast cell conclude that the mammary cell lines tested depend on specificity observed in this study. In one case, murine embry-BRCA1 for this important ubiquitination event and that other onic fibroblasts that lack exon 11 of BRCA1 have been made, cell lines, such as U2OS, which are unaffected by BRCA1 and these murine embryonic fibroblasts accumulate extra ceninhibition, rely on another factor to modify lysine 48 of y-tutrosomes in culture (46). Also, COS cells, which stably overbulin.
express a portion of BRCA1 that binds to y-tubulin, accumulate extra centrosomes (16) . The differences in cell type DISCUSSION specificity in centrosome amplification secondary to inhibition of BRCA1 function may be due to the natures of the assays Ever since it was discovered that BRCA1/BARD1 constiused in each study, or, alternatively, due to species specificity. tutes a highly active E3 ubiquitin ligase (15) , the key question
In the experiments in this study using adBIF, the centrosome has been the identification of the specific target of the BRCA1/ phenotype in human mammary cells occurred rapidly, within BARD1 ubiquitin ligase activity and the importance of this 24 h. The data in Fig. 1 characterize acute loss of BRCA1, not enzymatic reaction to the biology of the mammary cell. In this cells that have overcome loss of BRCA1 function after multistudy, we found that BRCA1/BARD1 ubiquitinates centrople divisions as in previously published studies. some proteins, including -y-tubulin. The ubiquitination of -y-tu-BRCA1 function has been implicated as important in DNA bulin is important for the maintenance of an appropriate cendamage repair pathways. There are multiple ways in which trosome number in the cell. Clearly, disruption of the proteins involved in genome maintenance regulate centrosome regulation of centrosome duplication by the loss of BRCA1 replication. As an example, the normal function of the p53 function, as in the mammary cells we tested, would lead to protein protects the cell from DNA damage, and mutant p53 harmful sequelae, such as aneuploidy and chromosomal instacan cause centrosome amplification (13) . In a different system, bility.
the fruit fly embryo, DNA damage caused depletion of y-tuThe ubiquitination of y-tubulin was remarkably specific.
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